Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial

BACKGROUND: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection with a hospital mortality in excess of 40%. Along with insufficient and delayed empirical antimicrobial therapy, inappropriate antimicrobial exposure has been identified to negatively affec...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Trials
Päätekijät: Hagel, Stefan, Fiedler, Sandra, Hohn, Andreas, Brinkmann, Alexander, Frey, Otto R., Hoyer, Heike, Schlattmann, Peter, Kiehntopf, Michael, Roberts, Jason A., Pletz, Mathias W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Study Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6554958/
https://ncbi.nlm.nih.gov/pubmed/31171029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-019-3437-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia